{"id":{"repo_id":"athens","oai_identifier":"oai:lib.uoa.gr:uoadl:3359618"},"canonical_url":"https://search.ndltd.org/etd/athens/oai:lib.uoa.gr:uoadl:3359618","repository":{"repo_id":"athens","name":"National and Kapodistrian University of Athens","base_url":"https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh"},"display":{"title":"Animal models of synucleinopathies","abstract":"Parkinson΄s disease (PD) is a neurodegenerative disorder that affects a large and ever-growing part of the population. Its effect on both the physical health but also the economic and social wellbeing of affected individuals is often disastrous. Due to this, PD and other neurodegenerative disorders have been thoroughly studied in the past, though much is still left unknown. Accumulation of aSyn aggregates in specific brain regions is a hallmark of Parkinson’s disease (PD) and related synucleinopathies. The propagation of aSyn has been suggested to be the underlying mechanism by which aggregates spread throughout the brain. The preformed fibril (PFF) aSyn striatal injection model has been widely utilized as an animal PD model, as it recapitulates many clinically relevant PD hallmarks, including aSyn aggregation, propagation, dopaminergic cell loss and behavioral deficits. Decreasing the levels of endogenous aSyn represents a promising approach for ameliorating PFF-induced aSyn pathology. The generation of novel brain-penetrant viral vectors (PHP.eB AAVs) opened up new horizons for the development of effective pan-CNS treatment for brain diseases. Towards this direction, we performed intravenous injections of PHP.eB AAVs engineered capsids, targeting the mouse aSyn (AAV-PHP.eB-CBA-eGFPmiRaSyn(mouse)x3-WPRE-bGHpA) and a scrambled control sequence (AAV-PHP.eb-CBA-eGFP-miNegx3-WPRE-bGHpA) in 8-week old C57/Bl6 male mice. One-week post-injection, human aSyn PFFs were unilaterally injected in the dorsal striatum in order to assess the effects of α-syn down-regulation on the seeding of PFF-induced pathology, at 3 months post-injection. During this investigation, behavioral and histochemical analyses were carried out to determine whether an improvement in phenotype would be observed in animals where aSyn had been downregulated in conjuncture with PFF injection. Herein, we demonstrate that intravenous administration of PHP.eB AAVs successfully enables widespread transduction throughout the CNS, including the substantia nigra, achieving efficient downregulation of endogenous rodent aSyn. Importantly, we show that aSyn PFFs injection triggers the formation of cytoplasmic inclusions of phosphorylated aSyn reminiscent of Lewy body pathology in brain regions directly interconnected with the injection site, with evident behavioral deficits already present by 3 months post-PFF intrastriatal inoculation. Our preliminary data suggest that AAV-mediated downregulation of endogenous aSyn reduces the accumulation of phosphorylated aSyn and mitigates motor impairment manifestations. Overall, we established a noninvasive delivery strategy, with high transduction efficacy to the CNS, which has prospects for the treatment of neurodegenerative diseases with widespread pathology such as a-synucleinopathies.","abstract_html":"Parkinson΄s disease (PD) is a neurodegenerative disorder that affects a large and ever-growing part of the population. Its effect on both the physical health but also the economic and social wellbeing of affected individuals is often disastrous. Due to this, PD and other neurodegenerative disorders have been thoroughly studied in the past, though much is still left unknown. Accumulation of aSyn aggregates in specific brain regions is a hallmark of Parkinson’s disease (PD) and related synucleinopathies. The propagation of aSyn has been suggested to be the underlying mechanism by which aggregates spread throughout the brain. The preformed fibril (PFF) aSyn striatal injection model has been widely utilized as an animal PD model, as it recapitulates many clinically relevant PD hallmarks, including aSyn aggregation, propagation, dopaminergic cell loss and behavioral deficits. Decreasing the levels of endogenous aSyn represents a promising approach for ameliorating PFF-induced aSyn pathology. The generation of novel brain-penetrant viral vectors (PHP.eB AAVs) opened up new horizons for the development of effective pan-CNS treatment for brain diseases. Towards this direction, we performed intravenous injections of PHP.eB AAVs engineered capsids, targeting the mouse aSyn (AAV-PHP.eB-CBA-eGFPmiRaSyn(mouse)x3-WPRE-bGHpA) and a scrambled control sequence (AAV-PHP.eb-CBA-eGFP-miNegx3-WPRE-bGHpA) in 8-week old C57/Bl6 male mice. One-week post-injection, human aSyn PFFs were unilaterally injected in the dorsal striatum in order to assess the effects of α-syn down-regulation on the seeding of PFF-induced pathology, at 3 months post-injection. During this investigation, behavioral and histochemical analyses were carried out to determine whether an improvement in phenotype would be observed in animals where aSyn had been downregulated in conjuncture with PFF injection. Herein, we demonstrate that intravenous administration of PHP.eB AAVs successfully enables widespread transduction throughout the CNS, including the substantia nigra, achieving efficient downregulation of endogenous rodent aSyn. Importantly, we show that aSyn PFFs injection triggers the formation of cytoplasmic inclusions of phosphorylated aSyn reminiscent of Lewy body pathology in brain regions directly interconnected with the injection site, with evident behavioral deficits already present by 3 months post-PFF intrastriatal inoculation. Our preliminary data suggest that AAV-mediated downregulation of endogenous aSyn reduces the accumulation of phosphorylated aSyn and mitigates motor impairment manifestations. Overall, we established a noninvasive delivery strategy, with high transduction efficacy to the CNS, which has prospects for the treatment of neurodegenerative diseases with widespread pathology such as a-synucleinopathies.","abstract_has_math":false,"creators":["Γιαλινάκη Έλενα","Gialinaki Elena"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-11-19T06:23:27Z","subjects":["Επιστήμες Υγείας","Health Sciences"],"languages":["English"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["uoadl:3359618"],"render_values":[{"text":"uoadl:3359618","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://pergamos.lib.uoa.gr/uoa/dl/object/3359618","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://pergamos.lib.uoa.gr/uoa/dl/object/3359618","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Alib.uoa.gr%3Auoadl%3A3359618","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Γιαλινάκη Έλενα","Gialinaki Elena"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2023"]},{"key":"dc:type","label":"Dc Type","values":["born_digital_postgraduate_thesis","Διπλωματική Εργασία","Postgraduate Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Επιστήμες Υγείας","Health Sciences"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["uoadl:3359618","https://pergamos.lib.uoa.gr/uoa/dl/object/3359618"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Parkinson΄s disease (PD) is a neurodegenerative disorder that affects a large and ever-growing part of the population. Its effect on both the physical health but also the economic and social wellbeing of affected individuals is often disastrous. Due to this, PD and other neurodegenerative disorders have been thoroughly studied in the past, though much is still left unknown. Accumulation of aSyn aggregates in specific brain regions is a hallmark of Parkinson’s disease (PD) and related synucleinopathies. The propagation of aSyn has been suggested to be the underlying mechanism by which aggregates spread throughout the brain. The preformed fibril (PFF) aSyn striatal injection model has been widely utilized as an animal PD model, as it recapitulates many clinically relevant PD hallmarks, including aSyn aggregation, propagation, dopaminergic cell loss and behavioral deficits. Decreasing the levels of endogenous aSyn represents a promising approach for ameliorating PFF-induced aSyn pathology. The generation of novel brain-penetrant viral vectors (PHP.eB AAVs) opened up new horizons for the development of effective pan-CNS treatment for brain diseases. Towards this direction, we performed intravenous injections of PHP.eB AAVs engineered capsids, targeting the mouse aSyn (AAV-PHP.eB-CBA-eGFPmiRaSyn(mouse)x3-WPRE-bGHpA) and a scrambled control sequence (AAV-PHP.eb-CBA-eGFP-miNegx3-WPRE-bGHpA) in 8-week old C57/Bl6 male mice. One-week post-injection, human aSyn PFFs were unilaterally injected in the dorsal striatum in order to assess the effects of α-syn down-regulation on the seeding of PFF-induced pathology, at 3 months post-injection. During this investigation, behavioral and histochemical analyses were carried out to determine whether an improvement in phenotype would be observed in animals where aSyn had been downregulated in conjuncture with PFF injection. Herein, we demonstrate that intravenous administration of PHP.eB AAVs successfully enables widespread transduction throughout the CNS, including the substantia nigra, achieving efficient downregulation of endogenous rodent aSyn. Importantly, we show that aSyn PFFs injection triggers the formation of cytoplasmic inclusions of phosphorylated aSyn reminiscent of Lewy body pathology in brain regions directly interconnected with the injection site, with evident behavioral deficits already present by 3 months post-PFF intrastriatal inoculation. Our preliminary data suggest that AAV-mediated downregulation of endogenous aSyn reduces the accumulation of phosphorylated aSyn and mitigates motor impairment manifestations. Overall, we established a noninvasive delivery strategy, with high transduction efficacy to the CNS, which has prospects for the treatment of neurodegenerative diseases with widespread pathology such as a-synucleinopathies."]},{"key":"dc:title","label":"Title","values":["Animal models of synucleinopathies"]}]}],"canonical_facts":{"dc:creator":["Γιαλινάκη Έλενα","Gialinaki Elena"],"dc:date":["2023"],"dc:description":["Parkinson΄s disease (PD) is a neurodegenerative disorder that affects a large and ever-growing part of the population. Its effect on both the physical health but also the economic and social wellbeing of affected individuals is often disastrous. Due to this, PD and other neurodegenerative disorders have been thoroughly studied in the past, though much is still left unknown. Accumulation of aSyn aggregates in specific brain regions is a hallmark of Parkinson’s disease (PD) and related synucleinopathies. The propagation of aSyn has been suggested to be the underlying mechanism by which aggregates spread throughout the brain. The preformed fibril (PFF) aSyn striatal injection model has been widely utilized as an animal PD model, as it recapitulates many clinically relevant PD hallmarks, including aSyn aggregation, propagation, dopaminergic cell loss and behavioral deficits. Decreasing the levels of endogenous aSyn represents a promising approach for ameliorating PFF-induced aSyn pathology. The generation of novel brain-penetrant viral vectors (PHP.eB AAVs) opened up new horizons for the development of effective pan-CNS treatment for brain diseases. Towards this direction, we performed intravenous injections of PHP.eB AAVs engineered capsids, targeting the mouse aSyn (AAV-PHP.eB-CBA-eGFPmiRaSyn(mouse)x3-WPRE-bGHpA) and a scrambled control sequence (AAV-PHP.eb-CBA-eGFP-miNegx3-WPRE-bGHpA) in 8-week old C57/Bl6 male mice. One-week post-injection, human aSyn PFFs were unilaterally injected in the dorsal striatum in order to assess the effects of α-syn down-regulation on the seeding of PFF-induced pathology, at 3 months post-injection. During this investigation, behavioral and histochemical analyses were carried out to determine whether an improvement in phenotype would be observed in animals where aSyn had been downregulated in conjuncture with PFF injection. Herein, we demonstrate that intravenous administration of PHP.eB AAVs successfully enables widespread transduction throughout the CNS, including the substantia nigra, achieving efficient downregulation of endogenous rodent aSyn. Importantly, we show that aSyn PFFs injection triggers the formation of cytoplasmic inclusions of phosphorylated aSyn reminiscent of Lewy body pathology in brain regions directly interconnected with the injection site, with evident behavioral deficits already present by 3 months post-PFF intrastriatal inoculation. Our preliminary data suggest that AAV-mediated downregulation of endogenous aSyn reduces the accumulation of phosphorylated aSyn and mitigates motor impairment manifestations. Overall, we established a noninvasive delivery strategy, with high transduction efficacy to the CNS, which has prospects for the treatment of neurodegenerative diseases with widespread pathology such as a-synucleinopathies."],"dc:identifier":["uoadl:3359618","https://pergamos.lib.uoa.gr/uoa/dl/object/3359618"],"dc:language":["English"],"dc:subject":["Επιστήμες Υγείας","Health Sciences"],"dc:title":["Animal models of synucleinopathies"],"dc:type":["born_digital_postgraduate_thesis","Διπλωματική Εργασία","Postgraduate Thesis"]},"updated_at":"2026-11-19T06:23:27Z"}